+44 7480725689Ting-Chou Chang
National Chung Cheng University, Taiwan
ScientificTracks Abstracts: Neurosci
In acute stroke, biomarker can not only differentiate true stroke patients from stoke mimicking conditions but also distinguish the difference between ischemic stroke (IS) and intracerebral hemorrhage (ICH). One of the stroke biomarkers, glial fibrillary acidic protein (GFAP) in acute stroke has been studied extensively in recent years. Several studies demonstrated a rapid increase to GFAP in blood samples of ICH patients compared to slow release in ischemic stroke. As the concentration of GFAP in blood is low, the detection is challenging. In this research, a rapid, high analytical sensitivity and selectivity based on fiber optic nanogoldlinked immunosorbent assay (FONLISA) technology is developed. The technology is based on the interaction of an analyte with a surface-immobilized capture antibody and a gold nanoparticle-labeled detection antibody to form a sandwich-like complex on a fiber core surface. The LOD for GFAP is 2.81 fg/mL with the linear dynamic range from 10 fg/mL to 1 ng/mL. On clinical GFAP detection with serum samples, totally 10 positive and 3 negative samples which checked by CT method are used. For ten positive samples, results from the FONLISA method are highly correlated (correlation coefficient, R = 0.98) with that from the ELISA method. For three negative samples, ELISA has one false-positive result, leading to a diagnostic specificity of 75%, while the specificity for FONLISA is 100%. In addition, the positive predictive value and test efficiency are 90.9% and 92.3% for ELISA, respectively, and 100% and 100% for FONLISA, respectively. The FONLISA method has advantages of short analysis time (about 15 min), high analytical sensitivity, good selectivity, inexpensive sensor chips, and also avoiding invasive procedures. We expect the immunosensor could be applicable to the point-of-care-testing (POCT) for diagnosis of GFAP in a patient-friendly manner.
Dr. Ting-Chou Chang received the PhD of Analytical Chemistry at 2015, and start on Post Doctoral Researcher of Center for Nano Bio-detection in National Chung Cheng University, Taiwan. My research focus on new technology of biosensor, integrate them into a device and commercialized. I have four patents which some of them have been licensing out to Instant NanoBiosensors. I have published the journal papers include binding kinetic constant evaluation method in FOPPR biosensor, FOPPR diagnostic assay development, the preconcentration and micro-mixing component development and singular nano-cone scattering array sensor. Now, I cooperate with Instant Nano Biosensors which is a startup company in Taiwan to develop the Biomarker Analyzer for binding kinetic and affinity analysis, epitope binning and immunoassay development. I established the data analysis model for binding kinetics, the assay for food safety and neurodegenerative disease such as traumatic brain injury, stroke and Alzheimer’s.
Menu